Dr. Nick Zdenkowski discusses the EMBER trial on second-line ER-targeted drugs, patient-reported outcome monitoring, and the survival benefits of risk-reducing surgeries for BRCA mutant patients.
00:00 - EMBER trial
01:41 - Patient-reported outcome monitoring
02:42 - BRCA mutant patients study